Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Christy J. Wilson

Christy J. Wilson

Sr. Director, Pharma and Biotech Segment

Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
Website:

About the author: Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution. Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market. Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).

Posts by Christy J. Wilson

How Drug Repurposing Is Revitalizing the Pharma Industry

Posted on October 16th, 2018 in Pharma R&D

The average expense of bringing a new drug to market has increased by more than 200 percent since the 1990s, with development costs regularly running into the billions. As pharma revenues continue to sink below the costs of creating commercially viable drugs, a growing number of developers are exploring a different approach: seeking out additional monetizable uses for drugs to which they already own intellectual property rights. (more…)

Drawbacks of Consumer Genetic Testing – And What Pharma Can Do To Make It Better

Posted on October 16th, 2018 in Pharma R&D

Genetic testing has become a big hit with consumers. Companies like Ancestry.com and 23andMe flood the airwaves with commercials about the joy of using DNA testing to find out about your heritage. But another reason genetic testing is attracting consumers is because it also can tell people about some of their genetic health risks. (more…)

The Delicate Balance of Drug Risks vs. Benefits

Posted on October 16th, 2018 in Pharma R&D

For many people, taking medication is a regular part of their daily routine, and these medicines are relied upon to treat disease and improve health.  The benefits of medicines are the helpful effects you get when you use them, such as the lowering blood pressure, curing infection, or relieving pain. (more…)

AI Can Work Wonders, But Can It Create Miracle Cures?

Posted on June 19th, 2018 in Pharma R&D

Modern technology seems downright magical at times. There are so many things that it can do for us at the push of a button, whether it’s our personal devices instantly retrieving information or massive industrial machines (more…)

  1. 1
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 13